Al-Chalabi, A., van den Berg, L.H. and Veldink, J. (2017) ‘Gene discovery in amyotrophic lateral sclerosis: implications for clinical management’, Nature Reviews Neurology, 13(2), pp. 96–104. Available at: https://doi.org/10.1038/nrneurol.2016.182.
Andreasson, U., Blennow, K. and Zetterberg, H. (2016) ‘Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders’, Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 3, pp. 98–102. Available at: https://doi.org/10.1016/j.dadm.2016.05.005.
Badders, N.M. et al. (2018) ‘Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy’, Nature Medicine, 24(4), pp. 427–437. Available at: https://doi.org/10.1038/nm.4500.
Beitel, L.K. et al. (2013) ‘Mechanisms Mediating Spinal and Bulbar Muscular Atrophy: Investigations into Polyglutamine-Expanded Androgen Receptor Function and Dysfunction’, Frontiers in Neurology, 4. Available at: https://doi.org/10.3389/fneur.2013.00053.
Belaya, K. et al. (2015) ‘Mutations in                              cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies’, Brain, 138(9), pp. 2493–2504. Available at: https://doi.org/10.1093/brain/awv185.
Benatar, M. et al. (2016) ‘ALS biomarkers for therapy development: State of the field and future directions’, Muscle & Nerve, 53(2), pp. 169–182. Available at: https://doi.org/10.1002/mus.24979.
Berlowitz, D.J. et al. (2016) ‘Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort’, Journal of Neurology, Neurosurgery & Psychiatry, 87(3), pp. 280–286. Available at: https://doi.org/10.1136/jnnp-2014-310055.
Birnkrant, D.J., Bushby, K., Bann, C.M., Apkon, S.D., Blackwell, A., Brumbaugh, D., et al. (2018) ‘Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management’, The Lancet Neurology, 17(3), pp. 251–267. Available at: https://doi.org/10.1016/S1474-4422(18)30024-3.
Birnkrant, D.J., Bushby, K., Bann, C.M., Alman, B.A., et al. (2018) ‘Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management’, The Lancet Neurology, 17(4), pp. 347–361. Available at: https://doi.org/10.1016/S1474-4422(18)30025-5.
Birnkrant, D.J., Bushby, K., Bann, C.M., Apkon, S.D., Blackwell, A., Colvin, M.K., et al. (2018) ‘Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan’, The Lancet Neurology, 17(5), pp. 445–455. Available at: https://doi.org/10.1016/S1474-4422(18)30026-7.
Bonanomi, D. and Pfaff, S.L. (2010) ‘Motor Axon Pathfinding’, Cold Spring Harbor Perspectives in Biology, 2(3), pp. a001735–a001735. Available at: https://doi.org/10.1101/cshperspect.a001735.
Brownstone, R.M. and Bui, T.V. (2010) ‘Spinal interneurons providing input to the final common path during locomotion’, in Breathe, Walk and Chew: The Neural Challenge: Part I. Elsevier, pp. 81–95. Available at: https://doi.org/10.1016/B978-0-444-53613-6.00006-X.
Carrì, M.T., D’Ambrosi, N. and Cozzolino, M. (2017) ‘Pathways to mitochondrial dysfunction in ALS pathogenesis’, Biochemical and Biophysical Research Communications, 483(4), pp. 1187–1193. Available at: https://doi.org/10.1016/j.bbrc.2016.07.055.
Cortes, C.J. et al. (2014) ‘Muscle Expression of Mutant Androgen Receptor Accounts for Systemic and Motor Neuron Disease Phenotypes in Spinal and Bulbar Muscular Atrophy’, Neuron, 82(2), pp. 295–307. Available at: https://doi.org/10.1016/j.neuron.2014.03.001.
Couratier, P. et al. (2016) ‘Epidemiology of amyotrophic lateral sclerosis: A review of literature’, Revue Neurologique, 172(1), pp. 37–45. Available at: https://doi.org/10.1016/j.neurol.2015.11.002.
Crisp, S.J., Kullmann, D.M. and Vincent, A. (2016a) ‘Autoimmune synaptopathies’, Nature Reviews Neuroscience, 17(2), pp. 103–117. Available at: https://doi.org/10.1038/nrn.2015.27.
Crisp, S.J., Kullmann, D.M. and Vincent, A. (2016b) ‘Autoimmune synaptopathies’, Nature Reviews Neuroscience, 17(2), pp. 103–117. Available at: https://doi.org/10.1038/nrn.2015.27.
Cruz, P.M.R., Palace, J. and Beeson, D. (2014) ‘Congenital myasthenic syndromes and the neuromuscular junction’, Current Opinion in Neurology, 27(5), pp. 566–575. Available at: https://doi.org/10.1097/WCO.0000000000000134.
Darabid, H., Perez-Gonzalez, A.P. and Robitaille, R. (2014) ‘Neuromuscular synaptogenesis: coordinating partners with multiple functions’, Nature Reviews Neuroscience, 15(11), pp. 703–718. Available at: https://doi.org/10.1038/nrn3821.
Dasen, J.S. and Jessell, T.M. (2009) ‘Chapter Six Hox Networks and the Origins of Motor Neuron Diversity’, in Hox Genes. Elsevier, pp. 169–200. Available at: https://doi.org/10.1016/S0070-2153(09)88006-X.
Drory, V.E. et al. (2001) ‘The value of muscle exercise in patients with amyotrophic lateral sclerosis’, Journal of the Neurological Sciences, 191(1–2), pp. 133–137. Available at: https://doi.org/10.1016/S0022-510X(01)00610-4.
Engel, A.G. et al. (2015) ‘Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment’, The Lancet Neurology, 14(4), pp. 420–434. Available at: https://doi.org/10.1016/S1474-4422(14)70201-7.
Finkel, R.S. et al. (2018) ‘Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics’, Neuromuscular Disorders, 28(3), pp. 197–207. Available at: https://doi.org/10.1016/j.nmd.2017.11.004.
Fratta, P. et al. (2014) ‘Correlation of clinical and molecular features in spinal bulbar muscular atrophy’, Neurology, 82(23), pp. 2077–2084. Available at: https://doi.org/10.1212/WNL.0000000000000507.
Fuller, G. and Manford, M. (2010) Neurology: an illustrated colour text. 3rd ed. Edinburgh: Churchill Livingstone Elsevier. Available at: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3669595080004761&institutionId=4761&customerId=4760.
Gendron, T.F. et al. (2017) ‘Poly(GP) proteins are a useful pharmacodynamic marker for                              -associated amyotrophic lateral sclerosis’, Science Translational Medicine, 9(383). Available at: https://doi.org/10.1126/scitranslmed.aai7866.
Gibson, S. and Haringer, V. (2015) ‘Amyotrophic lateral sclerosis: clinical perspectives’, Orphan Drugs: Research and Reviews [Preprint]. Available at: https://doi.org/10.2147/ODRR.S63585.
Gilhus, N.E. (2016) ‘Myasthenia Gravis’, New England Journal of Medicine, 375(26), pp. 2570–2581. Available at: https://doi.org/10.1056/NEJMra1602678.
Gordon, E., Rohrer, J.D. and Fox, N.C. (2016) ‘Advances in neuroimaging in frontotemporal dementia’, Journal of Neurochemistry, 138, pp. 193–210. Available at: https://doi.org/10.1111/jnc.13656.
Harland, R. (2000) ‘Neural induction’, Current Opinion in Genetics & Development, 10(4), pp. 357–362. Available at: https://doi.org/10.1016/S0959-437X(00)00096-4.
Harwood, C.A., McDermott, C.J. and Shaw, P.J. (2012) ‘Clinical aspects of motor neurone disease’, Medicine, 40(10), pp. 540–545. Available at: https://doi.org/10.1016/j.mpmed.2012.07.003.
Hughes, J. et al. (2011) ‘Principles of early drug discovery’, British Journal of Pharmacology, 162(6), pp. 1239–1249. Available at: https://doi.org/10.1111/j.1476-5381.2010.01127.x.
Jacobson, L. et al. (1999) ‘Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice’, Journal of Clinical Investigation, 103(7), pp. 1031–1038. Available at: https://doi.org/10.1172/JCI5943.
Jessell, T.M. (2000) ‘Neuronal specification in the spinal cord: inductive signals and transcriptional codes’, Nature Reviews Genetics, 1(1), pp. 20–29. Available at: https://doi.org/10.1038/35049541.
Jones, R.A. et al. (2017) ‘Cellular and Molecular Anatomy of the Human Neuromuscular Junction’, Cell Reports, 21(9), pp. 2348–2356. Available at: https://doi.org/10.1016/j.celrep.2017.11.008.
Kanning, K.C., Kaplan, A. and Henderson, C.E. (2010) ‘Motor Neuron Diversity in Development and Disease’, Annual Review of Neuroscience, 33(1), pp. 409–440. Available at: https://doi.org/10.1146/annurev.neuro.051508.135722.
Koneczny, I. et al. (2013) ‘MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters’, PLoS ONE, 8(11). Available at: https://doi.org/10.1371/journal.pone.0080695.
Koneczny, I., Cossins, J. and Vincent, A. (2014) ‘The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis’, Journal of Anatomy, 224(1), pp. 29–35. Available at: https://doi.org/10.1111/joa.12034.
Kusner, L.L. and Kaminski, H.J. (2015) ‘Myasthenia Gravis’, in Neurobiology of Brain Disorders. Elsevier, pp. 135–150. Available at: https://doi.org/10.1016/B978-0-12-398270-4.00010-0.
Ladle, D.R., Pecho-Vrieseling, E. and Arber, S. (2007) ‘Assembly of Motor Circuits in the Spinal Cord: Driven to Function by Genetic and Experience-Dependent Mechanisms’, Neuron, 56(2), pp. 270–283. Available at: https://doi.org/10.1016/j.neuron.2007.09.026.
Laurá, M. et al. (2018) ‘Prevalence and orthopedic management of foot and ankle deformities in Charcot-Marie-Tooth disease’, Muscle & Nerve, 57(2), pp. 255–259. Available at: https://doi.org/10.1002/mus.25724.
Leung, D.G. (2017) Other Proven and Putative Autoimmune Disorders of the Peripheral Nervous System. Oxford University Press. Available at: https://doi.org/10.1093/med/9780199937837.003.0098.
Li, L., Xiong, W.-C. and Mei, L. (2018) ‘Neuromuscular Junction Formation, Aging, and Disorders’, Annual Review of Physiology, 80(1), pp. 159–188. Available at: https://doi.org/10.1146/annurev-physiol-022516-034255.
Lieberman, A.P. et al. (2014) ‘Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy’, Cell Reports, 7(3), pp. 774–784. Available at: https://doi.org/10.1016/j.celrep.2014.02.008.
Lin, G., Mao, D. and Bellen, H.J. (2017) ‘Amyotrophic Lateral Sclerosis Pathogenesis Converges on Defects in Protein Homeostasis Associated with TDP-43 Mislocalization and Proteasome-Mediated Degradation Overload’, in Fly Models of Human Diseases. Elsevier, pp. 111–171. Available at: https://doi.org/10.1016/bs.ctdb.2016.07.004.
Lu, C.-H. et al. (2015) ‘Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis’, Neurology, 84(22), pp. 2247–2257. Available at: https://doi.org/10.1212/WNL.0000000000001642.
Malik, B. et al. (2011) ‘Absence of disturbed axonal transport in spinal and bulbar muscular atrophy’, Human Molecular Genetics, 20(9), pp. 1776–1786. Available at: https://doi.org/10.1093/hmg/ddr061.
Malik, B. et al. (2013) ‘Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy’, Brain, 136(3), pp. 926–943. Available at: https://doi.org/10.1093/brain/aws343.
Manzano, R. et al. (2018) ‘Beyond motor neurons: expanding the clinical spectrum in Kennedy’s disease’, Journal of Neurology, Neurosurgery & Psychiatry, 89(8), pp. 808–812. Available at: https://doi.org/10.1136/jnnp-2017-316961.
Maragakis, N.J. (2017) ‘What can we learn from the edaravone development program for ALS?’, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18(sup1), pp. 98–103. Available at: https://doi.org/10.1080/21678421.2017.1361446.
Mazzone, E.S. et al. (2017) ‘Revised upper limb module for spinal muscular atrophy: Development of a new module’, Muscle & Nerve, 55(6), pp. 869–874. Available at: https://doi.org/10.1002/mus.25430.
Mercuri, E. et al. (2018) ‘Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care’, Neuromuscular Disorders, 28(2), pp. 103–115. Available at: https://doi.org/10.1016/j.nmd.2017.11.005.
Meriggioli, M.N. and Sanders, D.B. (2009) ‘Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity’, The Lancet Neurology, 8(5), pp. 475–490. Available at: https://doi.org/10.1016/S1474-4422(09)70063-8.
Milioto, C. et al. (2017) ‘Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes’, Scientific Reports, 7(1). Available at: https://doi.org/10.1038/srep41046.
Mitsumoto, H., Brooks, B.R. and Silani, V. (2014) ‘Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?’, The Lancet Neurology, 13(11), pp. 1127–1138. Available at: https://doi.org/10.1016/S1474-4422(14)70129-2.
Monahan, Z., Shewmaker, F. and Pandey, U.B. (2016) ‘Stress granules at the intersection of autophagy and ALS’, Brain Research, 1649, pp. 189–200. Available at: https://doi.org/10.1016/j.brainres.2016.05.022.
Morgan, S. and Orrell, R.W. (2016) ‘Pathogenesis of amyotrophic lateral sclerosis’, British Medical Bulletin, 119(1), pp. 87–98. Available at: https://doi.org/10.1093/bmb/ldw026.
Morren, J.A. and Galvez-Jimenez, N. (2012) ‘Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis’, Expert Opinion on Investigational Drugs, 21(3), pp. 297–320. Available at: https://doi.org/10.1517/13543784.2012.657303.
‘Motor neurone disease: assessment and management | Guidance and guidelines | NICE’ (no date). Available at: https://www.nice.org.uk/guidance/ng42.
Nishimune, H. et al. (2008) ‘Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction’, The Journal of Cell Biology, 182(6), pp. 1201–1215. Available at: https://doi.org/10.1083/jcb.200805095.
O’Connor, E. et al. (2018) ‘Clinical and research strategies for limb-girdle congenital myasthenic syndromes’, Annals of the New York Academy of Sciences, 1412(1), pp. 102–112. Available at: https://doi.org/10.1111/nyas.13520.
Orrell, Richard WBarclay, Chris (no date) ‘Diagnosis and management of motor neurone disease’, Practitioner, 260, pp. 17–21. Available at: https://search.proquest.com/docview/1844334383/64C39DCAF3D346C0PQ/1?accountid=14511.
Otto, M. et al. (2012) ‘Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS’, Amyotrophic Lateral Sclerosis, 13(1), pp. 1–10. Available at: https://doi.org/10.3109/17482968.2011.627589.
Peragallo, J.H. (2017) ‘Pediatric Myasthenia Gravis’, Seminars in Pediatric Neurology, 24(2), pp. 116–121. Available at: https://doi.org/10.1016/j.spen.2017.04.003.
Ramdharry, G.M. et al. (2014) ‘A pilot study of proximal strength training in Charcot-Marie-Tooth disease’, Journal of the Peripheral Nervous System, 19(4), pp. 328–332. Available at: https://doi.org/10.1111/jns.12100.
Ramsey, D. et al. (2017) ‘Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool’, PLOS ONE, 12(2). Available at: https://doi.org/10.1371/journal.pone.0172346.
Reilly, M.M. et al. (2017) ‘221st ENMC International Workshop’:, Neuromuscular Disorders, 27(12), pp. 1138–1142. Available at: https://doi.org/10.1016/j.nmd.2017.09.005.
Renton, A.E., Chiò, A. and Traynor, B.J. (2014) ‘State of play in amyotrophic lateral sclerosis genetics’, Nature Neuroscience, 17(1), pp. 17–23. Available at: https://doi.org/10.1038/nn.3584.
Rodríguez Cruz, P.M. et al. (2014) ‘Congenital myopathies with secondary neuromuscular transmission defects; A case report and review of the literature’, Neuromuscular Disorders, 24(12), pp. 1103–1110. Available at: https://doi.org/10.1016/j.nmd.2014.07.005.
Rodríguez Cruz, P.M., Palace, J. and Beeson, D. (2014) ‘Inherited disorders of the neuromuscular junction: an update’, Journal of Neurology, 261(11), pp. 2234–2243. Available at: https://doi.org/10.1007/s00415-014-7520-7.
Rudolf, R. et al. (2014) ‘Degeneration of Neuromuscular Junction in Age and Dystrophy’, Frontiers in Aging Neuroscience, 6. Available at: https://doi.org/10.3389/fnagi.2014.00099.
Ruegsegger, C. and Saxena, S. (2016) ‘Proteostasis impairment in ALS’, Brain Research, 1648, pp. 571–579. Available at: https://doi.org/10.1016/j.brainres.2016.03.032.
Scoto, M. et al. (2017) ‘Therapeutic approaches for spinal muscular atrophy (SMA)’, Gene Therapy, 24(9), pp. 514–519. Available at: https://doi.org/10.1038/gt.2017.45.
Singhal, N. and Martin, P.T. (2011) ‘Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction’, Developmental Neurobiology, 71(11), pp. 982–1005. Available at: https://doi.org/10.1002/dneu.20953.
Spillane, J. et al. (2015) ‘Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca2+ channels’, Neurology, 84(6), pp. 575–579. Available at: https://doi.org/10.1212/WNL.0000000000001225.
Spillane, J., Beeson, D.J. and Kullmann, D.M. (2010) ‘Myasthenia and related disorders of the neuromuscular junction’, Journal of Neurology, Neurosurgery & Psychiatry, 81(8), pp. 850–857. Available at: https://doi.org/10.1136/jnnp.2008.169367.
Viegas, S. et al. (2012) ‘Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects’, Experimental Neurology, 234(2), pp. 506–512. Available at: https://doi.org/10.1016/j.expneurol.2012.01.025.
Vincent, A. (2002) ‘Unravelling the pathogenesis of myasthenia gravis’, Nature Reviews Immunology, 2(10), pp. 797–804. Available at: https://doi.org/10.1038/nri916.
‘Volume 58, Issue 3, March 2016’ (no date) Volume 58, Issue 3, March 2016 [Preprint]. Available at: https://link.springer.com/journal/12031/58/3.
Westerberg, E. et al. (2018) ‘The impact of physical exercise on neuromuscular function in Myasthenia gravis patients’, Medicine, 97(31). Available at: https://doi.org/10.1097/MD.0000000000011510.
Wolfe, G.I. et al. (2016) ‘Randomized Trial of Thymectomy in Myasthenia Gravis’, New England Journal of Medicine, 375(6), pp. 511–522. Available at: https://doi.org/10.1056/NEJMoa1602489.
Woollacott, I.O.C. and Rohrer, J.D. (2016) ‘The clinical spectrum of sporadic and familial forms of frontotemporal dementia’, Journal of Neurochemistry, 138, pp. 6–31. Available at: https://doi.org/10.1111/jnc.13654.